Equities Analysts Offer Predictions for NRXP Q1 Earnings

Key Points

• HC Wainwright projects NRx Pharmaceuticals will post Q1 2027 EPS of $0.14, reiterates a Buy rating with a $45.00 price target, while the Street consensus rates the stock a "Moderate Buy" with a consensus target of $38.25.
• NRx reported last quarter EPS of $0.19, beating estimates by $0.28, but revenue was just $0.98 million versus expectations of $7.53 million, highlighting a profit beat amid weak sales.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Free Report) - Research analysts at HC Wainwright issued their Q1 2027 earnings estimates for NRx Pharmaceuticals in a note issued to investors on Monday, April 27th. HC Wainwright analyst P. Trucchio expects that the company will post earnings per share of $0.14 for the quarter. HC Wainwright has a "Buy" rating and a $45.00 price target on the stock. The consensus estimate for NRx Pharmaceuticals' current full-year earnings is $0.13 per share. HC Wainwright also issued estimates for NRx Pharmaceuticals' Q2 2027 earnings at $0.24 EPS, Q3 2027 earnings at $0.36 EPS and Q4 2027 earnings at $0.48 EPS.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) last issued its quarterly earnings data on Monday, March 23rd. The company reported $0.19 EPS for the quarter, topping analysts' consensus estimates of ($0.09) by $0.28. The business had revenue of $0.98 million during the quarter, compared to analysts' expectations of $7.53 million.

A number of other equities analysts have also recently commented on NRXP. Zacks Research raised shares of NRx Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Monday, March 2nd. BTIG Research reissued a "buy" rating and issued a $25.00 price objective on shares of NRx Pharmaceuticals in a research note on Tuesday, March 24th. Weiss Ratings reissued a "sell (e+)" rating on shares of NRx Pharmaceuticals in a research note on Monday, December 29th. Ascendiant Capital Markets lifted their price objective on shares of NRx Pharmaceuticals from $48.00 to $49.00 and gave the stock a "buy" rating in a research note on Monday. Finally, D. Boral Capital reissued a "buy" rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a research note on Monday, April 20th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $38.25.

NRx Pharmaceuticals Stock Up 3.1%

Shares of NASDAQ:NRXP opened at $3.03 on Tuesday. NRx Pharmaceuticals has a 52 week low of $1.62 and a 52 week high of $3.84. The stock has a market capitalization of $100.20 million, a P/E ratio of -2.18 and a beta of 1.83. The firm has a fifty day simple moving average of $2.15 and a two-hundred day simple moving average of $2.33.

Hedge Funds Weigh In On NRx Pharmaceuticals

A number of large investors have recently made changes to their positions in NRXP. Geode Capital Management LLC boosted its stake in shares of NRx Pharmaceuticals by 27.9% during the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company's stock worth $562,000 after purchasing an additional 37,598 shares during the period. Ethos Financial Group LLC purchased a new position in shares of NRx Pharmaceuticals during the 3rd quarter worth about $39,000. One Wealth Management Investment & Advisory Services LLC boosted its stake in shares of NRx Pharmaceuticals by 86.1% during the 3rd quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company's stock worth $92,000 after purchasing an additional 12,950 shares during the period. AdvisorShares Investments LLC boosted its stake in shares of NRx Pharmaceuticals by 29.7% during the 3rd quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company's stock worth $1,129,000 after purchasing an additional 78,339 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of NRx Pharmaceuticals by 18.3% during the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company's stock worth $1,765,000 after purchasing an additional 82,781 shares during the period. 4.27% of the stock is owned by hedge funds and other institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company's research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx's pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.